Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2005

01-10-2005 | Review

Key stages of mammary gland development: Molecular mechanisms involved in the formation of the embryonic mammary gland

Authors: Julie R Hens, John J Wysolmerski

Published in: Breast Cancer Research | Issue 5/2005

Login to get access

Abstract

The development of the embryonic mammary gland involves communication between the epidermis and mesenchyme and is coordinated temporally and spatially by various signaling pathways. Although many more genes are likely to control mammary gland development, functional roles have been identified for Wnt, fibroblast growth factor, and parathyroid hormone-related protein signaling. This review describes what is known about the molecular mechanisms that regulate embryonic mammary gland development.
Appendix
Available only for authorised users
Literature
1.
Robinson GW, Karpf AB, Kratochwil K: Regulation of mammary gland development by tissue interaction. J Mammary Gland Biol Neoplasia. 1999, 4: 9-19. 10.1023/A:1018748418447.CrossRefPubMed
2.
Sakakura T: Mammary embryogenesis. The Mammary Gland: Development, Regulation and Function. Edited by: Neville MC, Daniel CW. 1987, New York: Plenum, 37-66.CrossRef
3.
Veltmaat JM, Mailleux AA, Thiery JP, Bellusci S: Mouse embryonic mammogenesis as a model for the molecular regulation of pattern formation. Differentiation. 2003, 71: 1-17. 10.1046/j.1432-0436.2003.700601.x.CrossRefPubMed
4.
Chu EY, Hens J, Andl T, Kairo A, Yamaguchi TP, Brisken C, Glick A, Wysolmerski JJ, Millar SE: Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development. 2004, 131: 4819-29. 10.1242/dev.01347.CrossRefPubMed
5.
Eblaghie MC, Song SJ, Kim JY, Akita K, Tickle C, Jung HS: Interactions between FGF and Wnt signals and Tbx3 gene expression in mammary gland initiation in mouse embryos. J Anat. 2004, 205: 1-13. 10.1111/j.0021-8782.2004.00309.x.CrossRefPubMedPubMedCentral
6.
Veltmaat JM, Van Veelen W, Thiery JP, Bellusci S: Identification of the mammary line in mouse by Wnt10b expression. Dev Dyn. 2004, 229: 349-56. 10.1002/dvdy.10441.CrossRefPubMed
7.
Mailleux AA, Spencer-Dene B, Dillon C, Ndiaye D, Savona-Baron C, Itoh N, Kato S, Dickson C, Thiery JP, Bellusci S: Role of FGF10/FGFR2b signaling during mammary gland development in the mouse embryo. Development. 2002, 129: 53-60.PubMed
8.
Bamshad M, Lin RC, Law DJ, Watkins WC, Krakowiak PA, Moore ME, Franceschini P, Lala R, Holmes LB, Gebuhr TC, Bruneau BG, Schinzel A, Seidman JG, Seidman CE, Jorde LB: Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nat Genet. 1997, 16: 311-5. 10.1038/ng0797-311.CrossRefPubMed
9.
Davenport TG, Jerome-Majewska LA, Papaioannou VE: Mammary gland, limb and yolk sac defects in mice lacking Tbx3, the gene mutated in human ulnar mammary syndrome. Development. 2003, 130: 2263-73. 10.1242/dev.00431.CrossRefPubMed
10.
van Genderen C, Okamura RM, Farinas I, Quo RG, Parslow TG, Bruhn L, Grosschedl R: Development of several organs that require inductive epithelial-mesenchymal interactions is impaired in LEF-1-deficient mice. Genes Dev. 1994, 8: 2691-703.CrossRefPubMed
11.
Chen J, Zhong Q, Wang J, Cameron RS, Borke JL, Isales CM, Bollag RJ: Microarray analysis of Tbx2-directed gene expression: a possible role in osteogenesis. Mol Cell Endocrinol. 2001, 177: 43-54. 10.1016/S0303-7207(01)00456-7.CrossRefPubMed
12.
Mustonen T, Ilmonen M, Pummila M, Kangas AT, Laurikkala J, Jaatinen R, Pispa J, Gaide O, Schneider P, Thesleff I, Mikkola ML: Ectodysplasin A1 promotes placodal cell fate during early morphogenesis of ectodermal appendages. Development. 2004, 131: 4907-19. 10.1242/dev.01377.CrossRefPubMed
13.
Sofaer JA: Aspects of the tabby-crinkled-downless syndrome. I. The development of tabby teeth. J Embryol Exp Morphol. 1969, 22: 181-205.PubMed
14.
Foley J, Dann P, Hong J, Cosgrove J, Dreyer B, Rimm D, Dunbar M, Philbrick W, Wysolmerski J: Parathyroid hormone-related protein maintains mammary epithelial fate and triggers nipple skin differentiation during embryonic breast development. Development. 2001, 128: 513-25.PubMed
15.
Phippard DJ, Weber-Hall SJ, Sharpe PT, Naylor MS, Jayatalake H, Maas R, Woo I, Roberts-Clark D, Francis-West PH, Liu YH, Maxson R, Hill RE, Dale TC: Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during foetal and postnatal mammary gland development. Development. 1996, 122: 2729-37.PubMed
16.
Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K, Maeda T, Takano Y, Uchiyama M, Heaney S, Peters H, Tang Z, Maxson R, Maas R: Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet. 2000, 24: 391-5. 10.1038/74231.CrossRefPubMed
17.
Wysolmerski JJ, Philbrick WM, Dunbar ME, Lanske B, Kronenberg H, Broadus AE: Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development. 1998, 125: 1285-94.PubMed
18.
Dunbar ME, Dann PR, Robinson GW, Hennighausen L, Zhang JP, Wysolmerski JJ: Parathyroid hormone-related protein signaling is necessary for sexual dimorphism during embryonic mammary development. Development. 1999, 126: 3485-93.PubMed
19.
Hennighausen L, Robinson GW: Signaling pathways in mammary gland development. Dev Cell. 2001, 1: 467-75. 10.1016/S1534-5807(01)00064-8.CrossRefPubMed
20.
Hovey RC, Trott JF, Vonderhaar BK: Establishing a framework for the functional mammary gland: from endocrinology to morphology. J Mammary Gland Biol Neoplasia. 2002, 7: 17-38. 10.1023/A:1015766322258.CrossRefPubMed
21.
Chakravarty G, Hadsell D, Buitrago W, Settleman J, Rosen JM: p190-B RhoGAP regulates mammary ductal morphogenesis. Mol Endocrinol. 2003, 17: 1054-1065. 10.1210/me.2002-0428.CrossRefPubMed
22.
Colletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, Wolf DM, Muller-Tidow C, Golub TR, Kawakami K, Ford HL: The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci USA. 2004, 101: 6478-6483. 10.1073/pnas.0401139101.CrossRef
Metadata
Title
Key stages of mammary gland development: Molecular mechanisms involved in the formation of the embryonic mammary gland
Authors
Julie R Hens
John J Wysolmerski
Publication date
01-10-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1306

Other articles of this Issue 5/2005

Breast Cancer Research 5/2005 Go to the issue

Research article

Se-methylselenocysteine inhibits phosphatidylinositol 3-kinase activity of mouse mammary epithelial tumor cells in vitro

Review

Overdiagnosis and overtreatment of breast cancer: Overdiagnosis in randomised controlled trials of breast cancer screening

Review

Imaging in breast cancer: Magnetic resonance imaging

Research article

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Viewpoint

Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitromodels

Review

Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits